What question did this study set out to answer?

Review the pathophysiology, diagnosis, evaluation, and modern management strategies for patients with X-linked hypophosphatemic rickets.

June 19, 2023Korean Journal of PediatricsOpen Access

X-linked hypophosphatemic rickets: from diagnosis to management

View Full Paper

Ask AI

Bookmark

Review the pathophysiology, diagnosis, evaluation, and modern management strategies for patients with X-linked hypophosphatemic rickets.
Examined limitations and adverse effects associated with conventional therapy, including oral phosphate salts and active vitamin D.
Summarized pathophysiological mechanisms and therapeutic applications of burosumab, an approved fibroblast growth factor-23 inhibitor.
Conventional therapy fails to completely resolve chronic hypophosphatemia, frequently resulting in incomplete healing, persistent skeletal deformities, and potential endocrine complications.
Targeted inhibition of fibroblast growth factor-23 via burosumab provides a mechanism-based treatment strategy to improve systemic phosphate regulation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical review uncovers diagnostic and therapeutic advancements for X-linked hypophosphatemia, highlighting the transition from conventional supplements to targeted fibroblast growth factor-23...

Cite This Study

Park et al. (2023) studied this question.

synapsesocial.com/papers/6a70ea30660549caf2c58f1a https://doi.org/10.3345/cep.2022.01459

View Full Paper

Ask AI

Bookmark

Implication

Clinical review uncovers diagnostic and therapeutic advancements for X-linked hypophosphatemia, highlighting the transition from conventional supplements to targeted fibroblast growth factor-23...

X-linked hypophosphatemic rickets: from diagnosis to management

Key Points

Discussion

Implication

Cite This Study

X-linked hypophosphatemic rickets: from diagnosis to management

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider